|
Presence of anti-glucose regulated protein78 autoantibodies in the sera of women with recurrent pregnancy loss
|
Behrooz Gharesifard *    1, Mohamad Hosein Karimi2 , Leila Bidar3 , Mohamad Ali Hassanzadeh4 |
1- Dept of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran , gharesifb@sums.ac.ir
2- Organ Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3- Infertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4- Dept of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran |
|
|
Abstract: (4359 Views) |
Introduction: Recurrent pregnancy loss (RPL) is defined as three or more miscarriages prior to the 20th week of gestation. This condition occurs in 15-20% of all pregnancies. Glucose-regulated protein 78 (GRP78) is an endoplasmic reticulum (ER) protein that is expressed on the trophoblast cells. The purpose of this study was to evaluate the presence of anti-GRP78 antibodies in the sera of women with RPL.
Materials & Methods: This case-control study was conducted 80 women referring to the Infertility Center of Shiraz University of Medical Sciences, Shiraz, Iran, during 2014-2016. The study population was assigned into two groups of case entailing 38 women with unexplained RPL and control including 42 healthy pregnant women with no history of miscarriage and a minimum of two successful pregnancies. The measurement of the anti-GRP78 antibody in the sera of the two groups was performed using the enzyme-linked immunosorbent assay (ELISA). Furthermore, western blot technique was used to assess the expression of GRP78 in placenta tissue for both groups.
Findings: The results of the western blot demonstrated the expression of GRP78 on the trophoblast cells in both groups. Furthermore, anti-GRP78 antibodies were detected in both case and control groups through ELISA. The case group had a lower level of anti-GRP78 antibodies; however, this difference was not statistically significant (P=0.1).
Discussion & Conclusions: The findings of the current study revealed no significant difference [Zamen1] between anti-GRP78 antibody level in RPL patients and healthy pregnant subjects.
|
|
| Keywords: pregnancy, RPL, placenta, GRP78 |
|
|
Full-Text [PDF 522 kb]
(1842 Downloads)
|
Type of Study: Applicable |
Received: 2017/10/26 | Accepted: 2018/02/5 | Published: 2018/09/15
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
